204 related articles for article (PubMed ID: 33689399)
21. Factors Associated with Head and Neck Cancer Postoperative Radiotherapy Delays: A Systematic Review and Meta-analysis.
Duckett KA; Kassir MF; Nguyen SA; Brennan EA; Chera BS; Sterba KR; Halbert CH; Hill EG; McCay J; Puram SV; Jackson RS; Sandulache VC; Kahmke R; Osazuwa-Peters N; Ramadan S; Nussenbaum B; Alberg AJ; Graboyes EM
Otolaryngol Head Neck Surg; 2024 Jun; ():. PubMed ID: 38842034
[TBL] [Abstract][Full Text] [Related]
22. Assessing the Risk of Adjuvant Radiotherapy Initiation Delays With Social Support Surveys.
Renslo B; Sawaf T; Virgen CG; Farrokhian N; Yu KM; Somani SN; Penn J; Ziegler A; Gan GN; Kakarala K; Shnayder Y; Bur AM; Sykes KJ
Otolaryngol Head Neck Surg; 2023 Oct; 169(4):928-937. PubMed ID: 36939526
[TBL] [Abstract][Full Text] [Related]
23. Factors Associated With the Choice of Radiation Therapy Treatment Facility in Head and Neck Cancer.
Sullivan CB; Al-Qurayshi Z; Anderson CM; Seaman AT; Pagedar NA
Laryngoscope; 2021 May; 131(5):1019-1025. PubMed ID: 32846018
[TBL] [Abstract][Full Text] [Related]
24. Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial.
Burtness B; Bourhis JP; Vermorken JB; Harrington KJ; Cohen EE
Trials; 2014 Nov; 15():469. PubMed ID: 25432788
[TBL] [Abstract][Full Text] [Related]
25. Relevance of the time interval between surgery and adjuvant radio (chemo) therapy in HPV-negative and advanced head and neck carcinoma of unknown primary (CUP).
Balk M; Rupp R; Mantsopoulos K; Allner M; Grundtner P; Mueller SK; Traxdorf M; Eckstein M; Speer S; Semrau S; Fietkau R; Iro H; Hecht M; Gostian AO
BMC Cancer; 2021 Nov; 21(1):1236. PubMed ID: 34794411
[TBL] [Abstract][Full Text] [Related]
26. A Phase 1 Study of Afatinib in Combination with Postoperative Radiation Therapy with and Without Weekly Docetaxel in Intermediate- and High-Risk Patients with Resected Squamous Cell Carcinoma of the Head and Neck.
Margalit DN; Haddad RI; Tishler RB; Chau NG; Schoenfeld JD; Bakst RL; Misiukiewicz KJ; Gupta V; Posner M; Hanna GJ; Mahmood U; Rawal B; Catalano PJ; Rath L; Bacay A; McHugh P; Rabinowits G
Int J Radiat Oncol Biol Phys; 2019 Sep; 105(1):132-139. PubMed ID: 31082494
[TBL] [Abstract][Full Text] [Related]
27. Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer.
Ang KK; Trotti A; Brown BW; Garden AS; Foote RL; Morrison WH; Geara FB; Klotch DW; Goepfert H; Peters LJ
Int J Radiat Oncol Biol Phys; 2001 Nov; 51(3):571-8. PubMed ID: 11597795
[TBL] [Abstract][Full Text] [Related]
28. Phase 1 study of EGFR-antisense DNA, cetuximab, and radiotherapy in head and neck cancer with preclinical correlatives.
Bauman JE; Duvvuri U; Thomas S; Gooding WE; Clump DA; Karlovits B; Wehbe A; Miller FR; Kim S; Sen M; Heron DE; Grandis JR; Argiris A
Cancer; 2018 Oct; 124(19):3881-3889. PubMed ID: 30291796
[TBL] [Abstract][Full Text] [Related]
29. Association between postoperative radiotherapy for young-onset head and neck cancer and long-term risk of second primary malignancy: a population-based study.
Zhu X; Zhou J; Zhou L; Zhang M; Gao C; Tao L
J Transl Med; 2022 Sep; 20(1):405. PubMed ID: 36064552
[TBL] [Abstract][Full Text] [Related]
30. Timely delivery of PORT for head and neck squamous cell carcinoma in a county hospital.
Rosas Herrera AM; Haskins AD; Hanania AN; Jhaveri PM; Chapman CH; Huang Q; Hernandez DJ
Laryngoscope Investig Otolaryngol; 2024 Feb; 9(1):e1211. PubMed ID: 38362185
[TBL] [Abstract][Full Text] [Related]
31. Intratumor heterogeneity could inform the use and type of postoperative adjuvant therapy in patients with head and neck squamous cell carcinoma.
Mroz EA; Patel KB; Rocco JW
Cancer; 2020 Jan; 126(9):1895-1904. PubMed ID: 32083741
[TBL] [Abstract][Full Text] [Related]
32. Explaining Racial Disparities in Surgically Treated Head and Neck Cancer.
Jassal JS; Cramer JD
Laryngoscope; 2021 May; 131(5):1053-1059. PubMed ID: 33107610
[TBL] [Abstract][Full Text] [Related]
33. Tumor DNA-methylome derived epigenetic fingerprint identifies HPV-negative head and neck patients at risk for locoregional recurrence after postoperative radiochemotherapy.
Tawk B; Wirkner U; Schwager C; Rein K; Zaoui K; Federspil PA; Adeberg S; Linge A; Ganswindt U; Hess J; Unger K; Tinhofer I; Budach V; Lohaus F; Krause M; Guberina M; Stuschke M; Balermpas P; Rödel C; Grosu AL; Schäfer H; Zips D; Combs SE; Pigorsch S; Zitzelsberger H; Baumeister P; Kirchner T; Bewerunge-Hudler M; Weichert W; Hess J; Herpel E; Belka C; Baumann M; Debus J; Abdollahi A;
Int J Cancer; 2022 Feb; 150(4):603-616. PubMed ID: 34648658
[TBL] [Abstract][Full Text] [Related]
34. Evolution of treatment and high-risk features in resectable locally advanced Head and Neck squamous cell carcinoma with special reference to extracapsular extension of nodal disease.
Krstevska V
J BUON; 2015; 20(4):943-53. PubMed ID: 26416042
[TBL] [Abstract][Full Text] [Related]
35. Evaluating Adjuvant Therapy With Chemoradiation vs Radiation Alone for Patients With HPV-Negative N2a Head and Neck Cancer.
Yan F; Li H; Kaczmar JM; Sharma AK; Day TA; Neskey DM; Pipkorn P; Zenga J; Graboyes EM
JAMA Otolaryngol Head Neck Surg; 2020 Dec; 146(12):1109-1119. PubMed ID: 32790830
[TBL] [Abstract][Full Text] [Related]
36. A comparison of treatment outcomes by radiochemotherapy and postoperative radiotherapy in locally advanced squamous cell carcinomas of head and neck.
Fortin A; Caouette R; Wang CS; Vigneault E
Am J Clin Oncol; 2008 Aug; 31(4):379-83. PubMed ID: 18845998
[TBL] [Abstract][Full Text] [Related]
37. Feasibility and efficacy of accelerated weekly concomitant boost postoperative radiation therapy combined with concomitant chemotherapy in patients with locally advanced head and neck cancer.
Pehlivan B; Luthi F; Matzinger O; Betz M; Dragusanu D; Bulling S; Bron L; Pasche P; Seelentag W; Mirimanoff RO; Zouhair A; Ozsahin M
Ann Surg Oncol; 2009 May; 16(5):1337-43. PubMed ID: 19280263
[TBL] [Abstract][Full Text] [Related]
38. Induction paclitaxel, carboplatin, and infusional 5-FU followed by concurrent radiation therapy and weekly paclitaxel/carboplatin in the treatment of locally advanced head and neck cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Meluch AA; McClurkan S; Gray JR; Stroup SL; Burris HA; Yardley DA; Bradof JE; Yost K; Ellis JK; Greco FA
Cancer J; 2002; 8(4):311-21. PubMed ID: 12184409
[TBL] [Abstract][Full Text] [Related]
39. A contemporary analysis of racial disparities in recommended and received treatment for head and neck cancer.
Nocon CC; Ajmani GS; Bhayani MK
Cancer; 2020 Jan; 126(2):381-389. PubMed ID: 31580491
[TBL] [Abstract][Full Text] [Related]
40. Feasibility and acceptability of combining cognitive behavioural therapy techniques with swallowing therapy in head and neck cancer dysphagia.
Patterson JM; Fay M; Exley C; McColl E; Breckons M; Deary V
BMC Cancer; 2018 Jan; 18(1):1. PubMed ID: 29291726
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
